scholarly journals Fire-Induced Pressure Response and Failure Characterization of PCV/SCV/3013 Containers - Phase 1.

2019 ◽  
Author(s):  
Hector Mendoza ◽  
Walter Gill ◽  
Ray Sprankle ◽  
Alex Shefferman ◽  
Victor Figueroa ◽  
...  
Keyword(s):  
Phase 1 ◽  
Pressure Response

Characterization of Pressure Response of Bragg Gratings in Grapefruit Microstructured Fibers

2010 ◽  
Vol 28 (9) ◽  
pp. 1392-1397 ◽  
Author(s):  
Chuang Wu ◽  
Bai-Ou Guan ◽  
Zhi Wang ◽  
Xinhuan Feng
Keyword(s):  
Bragg Gratings ◽  
Pressure Response ◽  
Microstructured Fibers

scholarly journals LANL Phase 3 Container Loading in Support of the Fire-Induced Pressure Response and Failure Characterization of PCV/SCV/3013 Containers

2020 ◽  
Author(s):  
Joshua Edward Narlesky ◽  
Curtis W. Emms ◽  
David C. Tung ◽  
Jared Tyler Stritzinger ◽  
Dakota James Gregory ◽  
...  
Keyword(s):  
Pressure Response ◽  
Phase 3 ◽  
Container Loading

scholarly journals LANL Phase 3 Test Plan For Container Loading to Support the Fire-Induced Pressure Response and Failure Characterization of PCV/SCV/3013 Containers

2019 ◽  
Author(s):  
Joshua Edward Narlesky ◽  
Curtis W. Emms ◽  
David C. Tung ◽  
Jared Tyler Stritzinger ◽  
Luke Simms ◽  
...  
Keyword(s):  
Pressure Response ◽  
Test Plan ◽  
Phase 3 ◽  
Container Loading

Characterization of Dynamic Pressure Response in Vertical Two Phase Flow

2017 ◽  
Vol 08 (01) ◽  
Author(s):  
Agbakwuru J ◽  
Ogunlana A ◽  
Oshagbemi O ◽  
Rahman MA ◽  
Imtiaz S
Keyword(s):  
Two Phase Flow ◽  
Dynamic Pressure ◽  
Pressure Response ◽  
Phase Flow ◽  
Two Phase

Abstract 2786: Identification and preclinical characterization of EMD 1204831 – A selective c-Met kinase inhibitor in clinical phase 1

2011 ◽  
Author(s):  
Friedhelm Bladt ◽  
Andree Blaukat ◽  
Dieter Dorsch ◽  
Claus Fittschen ◽  
Manja Friese-Hamim ◽  
...  
Keyword(s):  
Kinase Inhibitor ◽  
Phase 1 ◽  
Clinical Phase

Microstructure Characterization of Ni-V Splat Quenched Foils

1997 ◽  
Vol 3 (S2) ◽  
pp. 694-695
Author(s):  
H. Sieber ◽  
D.R. Allen ◽  
J. Perepezko
Keyword(s):  
Cooling Rate ◽  
Cross Section ◽  
Phase 1 ◽  
Nucleation And Growth ◽  
Growth Behavior ◽  
Plan View ◽  
Σ Phase ◽  
Rate Dependent ◽  
Section Sample

Although the thickness of splat quenched (SQ) foils is normally less then 100 μm the solidified microstructure is usually not homogenous, but rather is determined by a cooling rate dependent nucleation and growth behavior of the different phases. The cooling rate and thus the microstructure changes significantly with distance from the edge to the middle of the SQ foils. Rapidly quenched nickel-vanadium (Ni-V) foils consist of three phases formed during solidification, a Ni-fcc, a V-bcc and a intermetallic σ phase [1-3]. To interpret the microstructure evolution in detail, a special TEM cross section sample preparation was applied. The SQ foil was ground to 30 μm, glued on a copper grid and ion-milled parallel to the foils (Fig.1a). In Ni-49V SQ foils seven typical microstructure regions (see Fig. 1 b) could be identified and were analyzed in detail by TEM investigations in plan view and cross section geometries. Furthermore, three solidification pathways were identified.

A phase I study of LOXO-292, a highly selective RET inhibitor, in pediatric patients with RET-altered cancers.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. TPS10066-TPS10066 ◽  
Author(s):  
Steven G. DuBois ◽  
Catherine Michelle Albert ◽  
Leo Mascarenhas ◽  
Theodore Willis Laetsch ◽  
Cornelis Martinus van Tilburg ◽  
...  
Keyword(s):  
Dose Escalation ◽  
Phase 1 ◽  
Point Mutations ◽  
Primary Objective ◽  
Clinical Activity ◽  
Resistance Mutations ◽  
Eligibility Criteria ◽  
Molecular Abnormalities ◽  
Anti Tumor Activity

TPS10066 Background: Genomic alterations in the RET kinase, including gene fusions and activating point mutations, are implicated in the pathogenesis of lung, thyroid, sarcoma and other cancers in both chidren and adults. Currently available multikinase inhibitors with anti-RET activity are non-selective and may be associated with less favorable toxicity profile. LOXO-292 is a novel, highly selective, ATP-competitive small molecule RET inhibitor. LOXO-292 has preclinical nanomolar potency against diverse RET alterations (e.g. fusions, activating mutations and anticipated acquired resistance mutations) and anti-tumor activity in the brain. LOXO-292 has demonstrated clinical activity in adult patients with RET-alterated solid tumors. Methods: LIBRETTO-121 (EudraCT 2019-000212-28) is an ongoing multicenter phase 1/2 dose escalation multicenter trial in patients 6 months-21 years of age with advanced, RET-altered solid and CNS tumors. Dose escalation follows a rolling 6 design starting at the equivalent of the adult recommended phase 2 dose. Enrollment began on 12 Feb 2019 and is ongoing. Key eligibility criteria include: solid or CNS tumor with a documented RET gene alteration refractory to standard therapy; age 6 months to 21 years of age; and adequate bone marrow, liver and kidney function. LOXO-292 is administered orally BID for continuous 28-day cycles. Both capsule and liquid suspension dosage forms are available. The primary objective of the phase 1 portion of the study is to determine safety and dose limiting toxicities. Key secondary objectives include characterization of pharmacokinetic properties, identification of the MTD and initial characterization of the anti-tumor activity of LOXO-292. Archival tissue will be used to further characterize molecular abnormalities. Clinical trial information: 2019-000212-28.

Sign in / Sign up

Export Citation Format

Share Document